glp-1 market share by company Overview: Agonists and the Obesity Market | Blog GLP-1 Receptor Agonist Market Size
Description
Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year
Why patients love VOL
Ships FREE every 2 months - 120 scoops
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
